Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunomedix (US) presents early LeukoScan data:

This article was originally published in Clinica

Executive Summary

Immunomedix (US) says its infectious disease diagnostic, LeukoScan, is at least as good as indium-111 white blood cell imaging, but much easier to perform. The data, presented on June 12th at the Society of Nuclear Medicine's annual meeting (Pines Bay, Florida), come from one of the 14 Phase III trial sites. Immunomedix is currently assessing clinical data on bone infection and diabetic foot ulcers. Phase IIIs on prosthesis infection and appendicitis are continuing.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT092017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel